All In Biotech

Drug Trial Radar · NCT06900049

Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy

Evaluation of the Safety, Tolerability, and Efficacy of a Single Intravenous Injection of LE051 in Patients With Duchenne Muscular Dystrophy (DMD)

Last checked: Nov 20, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Oct 24, 2024

Primary completion

Sep 20, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 4 years, up to 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of LE051 intravenous therapy in DMD patients treated with exon 51 skipping therapy.

Conditions

  • Duchenne Muscular Dystrophy (DMD)

Interventions

  • LE051Drug

    LE051 dose escalation : dose 1 and dose 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of AEs, SAEsTime frame: from day 1 to week 52 after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.